News: Immunogen Inc (IMGN.OQ)
IMGN.OQ on NASDAQ Stock Exchange Global Select Market
19.38USD
1 Aug 2013
19.38USD
1 Aug 2013
Price Change (% chg)
$0.33 (+1.73%)
$0.33 (+1.73%)
Prev Close
$19.05
$19.05
Open
$19.25
$19.25
Day's High
$19.44
$19.44
Day's Low
$18.98
$18.98
Volume
247,131
247,131
Avg. Vol
210,169
210,169
52-wk High
$19.98
$19.98
52-wk Low
$10.85
$10.85
Select another date:
Fri, Feb 22 2013
CORRECTED-UPDATE 3-FDA approves Roche drug for late-stage breast cancer
(Corrects paragraph 5 to show control arm included Xeloda, not Herceptin)
UPDATE 3-FDA approves Roche drug for late-stage breast cancer
* ImmunoGen shares up 1.9 pct; Roche up 1.5 pct (Adds additional analyst comment, background)
Select another date:
- Five Keys To Making A Cancer Smart Bomb Go 'BOOM!'
- 3 Biotech Stocks Spiking on Big Volume
- Immunogen: A Game Changing Stock With Tremendous Upside Potential
- Cramer's Mad Money - Noodles & Company Is The Son Of Chipotle (7/1/13)
- 2 Small, Great Biotechs Underestimated By The Market
- Sorrento Has Multiple Shots On Goal, Worth A Closer Look
Press Releases
- ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
- ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd Annual Healthcare Conference
- ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
- ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
- ImmunoGen, Inc. Announces FDA Has Granted Priority Review Status to the Trastuzumab Emtansine (T-DM1) Marketing Application
- ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
- ImmunoGen, Inc. Reports First Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
- ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results
- ImmunoGen, Inc. Announces Overall Survival Data Reported for Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial
- ImmunoGen, Inc. Announces Presentation of New IMGN901 Clinical Data

